Short Summary
Mercedes‑Benz and Phelan Group settled their IPR dispute over U.S. Patent 10,259,465 B2. The Board granted a joint motion to terminate the proceeding and treated the settlement agreement as confidential business information.
Detailed Summary
In IPR2025-00919, Mercedes‑Benz Group AG challenged U.S. Patent 10,259,465 B2 owned by Phelan Group, LLC. After the trial was instituted on November 21, 2025, the parties reached a settlement covering all related disputes, including those pending in the District Court. They filed a joint motion to terminate the inter partes review under 35 U.S.C. § 317(a) and to keep the settlement agreement confidential under 37 C.F.R. § 42.74(c). The Patent Trial and Appeal Board granted both requests, formally terminating the proceeding and ordering the settlement agreement to be treated as business‑confidential information.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Mercedes-Benz Group AG et al. vs Phelan Group, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Imperative Care, Inc.vsInari Medical, Inc. et al.
Imperative Care has filed an IPR petition seeking to invalidate Inari Medical’s 12,239,333 patent covering clot‑removal devices. The petition relies on multiple prior‑art references to argue anticipation and obviousness of the asserted claims. The Board must decide whether to institute the review.
Bruker Spatial Biology, Inc.vs10x Genomics, Inc. et al.
Bruker Spatial Biology, Inc. and 10x Genomics jointly asked the PTAB to file their settlement agreement as business‑confidential information and keep it separate from the patent file. The request invokes 35 U.S.C. § 317 and related regulations to protect the settlement details.
Samsung Electronics Co., Ltd. et al.vsWilus Institute of Standards and Technology Inc.
Samsung contests the patent owner’s arguments that the Lee and Choudhury references do not teach the claimed BSS‑color disabling features. The petitioner seeks denial of the patent owner’s Director Review request, keeping the IPR instituted.
JinkoSolar Holding Co., Ltd. et al.vsFirst Solar, Inc.
JinkoSolar has filed an IPR petition seeking cancellation of all eight claims of First Solar’s 9,130,074 patent, alleging lack of novelty and obviousness over multiple prior‑art references. The petition relies on Tamura, Borden, Rana and combinations with Gan, Kwark, and Swanson.
FRESH PRODUCTS, LLCvsSANASTAR INC.
Fresh Products has filed an IPR petition seeking cancellation of 16 claims of Sanastar’s urinal anti‑splash patent, asserting that the claims are obvious over earlier splash‑prevention devices such as Fushimi, Brown, Valadez, and Wise.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.